For patients whose cancer has returned, First Ascent Biomedical provides new ways to fight by combining functional drug testing, genomics, and artificial intelligence to design an individualized treatment plan in a week for each patient. Our technology rapidly grows tumor bulk, more importantly chemo-resistant cells enabling the testing 100s of FDA-approved drugs to measure the cellular response of both cell populations. This is the key dataset for the AI engine, supported by genomics data to identify every cancer weakness and identify which drugs work. To Learn More- Contact us at: [email protected] Or go to: www.FirstAscentBio.com
First Ascent Biomedical的外部链接
The future of FPM is now!
It is heartbreaking when you read, “They spend time and resources on a treatment plan I knew wouldn’t have worked,” she said. “And that makes me feel sad because the patient lost time.”?This speaks directly to the power of personalization and delivering results in a clinically actionable timeframe, as we have demonstrated in our April 2024 Nature Medicine publication. Functional Precision Medicine is the future.
Thank you to Fast Company and Kolawole Samuel Adebayo (KSA) for highlighting how technology like First Ascent Biomedical and others are all working towards one goal: Tackling Cancer! #cancer #curecancer #FPM #FunctionalPrecisionMedicine
What a great article in Fast Company and how precision medicine is tackling stubborn cancers in 2024. I appreciate Kolawole Samuel Adebayo (KSA) acknowledging the work of First Ascent Biomedical's co-founder Diana Azzam, PhD, highlighting that "even though two people with the same cancer might get the same medicine, they can have very different outcomes.” It sounds so simple, but it is true, which is why precision medicine will play a critical role in fighting cancer today and into the future. It's about the right drug for the right patient at the right time. https://lnkd.in/gNRvvxmR #precisionmedicine #cancer #cancerresearch
Exciting news! Check out this powerful podcast featuring our co-founder, Diana Azzam, PhD . From her early days in Lebanon, growing up in the UAE, to earning her PhD in the US, Diana's journey is truly inspiring. As a leader in Functional Precision Medicine (FPM) at First Ascent Biomedical, she's making waves in the industry. Our recent publication in Nature Medicine reveals that cancer patients treated with our FPM approach saw an astonishing 83% improvement in progression-free survival compared to standard treatments. Listen in to learn more about our innovative work and Diana's incredible story! Thank you, Biorasi and Chris O'Brien for the interview! Fighting cancer is a team sport. Thank you for being part of that team. Together we will beat cancer. #firstascentbio #curecancer #cancerresearch
“Our studies are open for those that have exhausted standard of care, and we're showing improved responses, and the data is promising. So, I really hope that as we scale up and generate more data, we can actually move to newly diagnosed patients.” - Diana Azzam, PhD, Assistant Professor at Florida International University, Co-Founder at First Ascent Biomedical Welcome to the latest episode of Biorasi's Few & Far Between podcast. Join host Chris O'Brien and guest, Diana Azzam, as they discuss technological innovations in guiding individualized patient treatments. Tune in today! Find this new episode on your favorite streaming platform or visit >> https://bit.ly/2RvKoJg #YourGoToCRO #Biorasi2024 #CROs #clinicaltrials #oncology #FIU
Looking back on a phenomenal #ASCO24 earlier this month, we're energized by the positive outlook across the oncology landscape. Our Functional Precision Medicine (FPM) posters sparked great interest, validating #FPM as the future of cancer care. We're thrilled to lead this transformative approach. ?? Click here for our posters:?https://lnkd.in/gE93Ekzp Connecting with patient advocacy groups like Know Your Lemons Foundation, Triage Cancer, Colorectal Cancer Alliance, Pancreatic Cancer Action Network was a highlight. As we improve patient outcomes, potential collaborations are ahead. ASCO?reinforced our commitment to revolutionizing precision oncology alongside partners who share our vision. Grateful for the progress and counting down to next year! #PrecisionOncology #FunctionalPrecisionMedicine #PatientAdvocacy #CancerResearch
Thank you, David Moulton and Palo Alto Networks, for spotlighting our CEO, Jim Foote. On their podcast, he discusses how personal experience with his son's cancer diagnosis drove him to apply cybersecurity principles to developing a platform that helps patients today by providing individualized cancer treatment plans,?accelerating new drugs into the clinic for patients tomorrow, and reshaping cancer treatment for the?patients of the?future. Listen in, and let us know what you think! #oncology #functionalprecisionmedicine #ai #cancer
CISO ?? Biotech leader ???? In this episode of Threat Vector, Jim Foote, CEO of First Ascent Biomedical, shares how his son's cancer diagnosis inspired him to apply cybersecurity principles to Functional Precision Medicine, tailoring cancer treatments to each patient. ??? Don't miss this powerful conversation. https://bit.ly/3VRlxht
Last week, our CTO Noah Berlow joined the best minds in biotech and healthcare for the inaugural Biotech Day Summit. Hosted by Phase Capital and 615.vc, this stellar event brought together over 150 innovators, investors, and academics from 13 states across the nation. The highlight? A riveting panel on "The Role of AI in Revolutionizing Biotech and Healthcare" moderated by Dr. Chase Spurlock. Noah shared the stage with visionaries from Minnow Ventures, HistAI, and Amazon for a fascinating exploration of AI's boundless potential, and how First Ascent Biomedical is leading the way, using AI and FPM to help guide cancer treatment. Chase Spurlock Maya Frutiger Katherine Ivanova Shakthi Kumar A huge shoutout to Kavya Sharman, Oliver Muoto, and the organizers for assembling such an incredible event! Kavya Sharman, PhD Oliver Muoto
The Decode Health team was thrilled to attend last week's inaugural Biotech Day Summit, hosted by Phase Capital and 615.vc. Over 150 biotech startups, investors, academic leaders, and strategic partners representing 13 states joined for the day's activities. Our CEO, Dr. Chase Spurlock, moderated a panel - the "Role of AI in Revolutionizing Biotech and Healthcare" with Dr. Shakthi Kumar and representatives from Minnow Ventures (Maya Frutiger), HistAI (Katherine I.), and First Ascent Biomedical (Noah Berlow). In a wide-ranging conversation, the panel discussed approaches to vet new AI-enabled companies and efficiently leverage AI tools and emerging technologies, including quantum computing, to accelerate new discoveries. A special thank you to Kavya Sharman, PhD and Oliver Muoto for bringing everyone together. #NashvilleBioTech #Genomics #MachineLearning #AI #Healthcare
Attending BioTech Summit Day? Be sure to say hello to our co-founder and CTO, Noah Berlow!
Co-Founder & CTO (First Ascent Biomedical) | Techstars Boston 2021 | Assistant Member (cc-TDI)
Excited to share that I’ll be speaking on the Role of AI in Revolutionizing Biotech and Healthcare at the BioTech Day Summit in Franklin, TN on June 14th! I look forward to discussing the numerous ways the interface of AI and biotech will change paradigms and improve outcomes for patients, payers, and pharma. For more details, visit: https://lnkd.in/eFyb9u5M ? #FirstAscent #AI #PersonalizedMedicine Diana Azzam, PhD Jim Foote First Ascent Biomedical
Always inspired by the power of family support to get us through the tough time.
Creating policies to incentivize biopharma to develop drugs for kids — PRV — Give Kids a Chance Act HR 3433 — RACE for Children Act
Thank you, Jake Tapper and CNN, for bringing me on the air. If there are as many pediatric cancers as adult cancers, and if few of those pediatric cancers have treatments that enable kids to lead long and healthy lives, then why isn't half NCI's budget dedicated to childhood cancer research?
We are excited about what is possible when biology and technology work in concert to help patients in need! Thank you to all who stopped by our #ASCO2024 Poster Presentations. Questions? Please comment below or email Noah Berlow, [email protected].
Co-Founder & CTO (First Ascent Biomedical) | Techstars Boston 2021 | Assistant Member (cc-TDI)
First Ascent's first ASCO has been a huge success! We presented our two abstracts and posters to physicians, pharma experts, and patients. People from across the industry and around the world were surprised at what was possible when biology and technology work in concert to help patients in need. The excitement around our groundbreaking personalized medicine platform continues to grow, and our explainable AI biomarker presentation was especially busy. The feedback was unanimously positive in support of our vision of the future of personalized cancer treatments, with myriad versions of "Congratulations, this is amazing work". https://lnkd.in/eVa66v_b https://lnkd.in/e3dideiN #FunctionalPrecisionMedicine #AI #MultiOmicsBiomarkers #ASCO2024 Diana Azzam, PhD Jim Foote First Ascent Biomedical
The poster we presented at ASCO yesterday was well received. We showed the power combining biology with machine learning and the impact we can have on biomarker development, helping patients, and advancing drug discovery for pharmaceutical companies. Thank you to Live Like Bella? Childhood Cancer Foundation, Techstars, TREY FOOTE FOUNDATION, National Science Foundation (NSF) and The National Institutes of Health who all played a role in making this research possible. Together we will beat cancer.